Today, on
Resolution on adoption of accounts and allocation of the company's result
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet. The annual general meeting also resolved to distribute the company's result in accordance with the proposal from the board of directors in the annual report meaning that no dividends are paid for the financial year 2020/2021 and that the available funds are carried forward.
Discharge from liability for the members of the board of directors and the CEO
The annual general meeting resolved to discharge the members of the board of directors and the CEO from liability for the financial year 2020/2021.
Election and remuneration of the board of directors and auditors
The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect Anders Månsson, Christer Fåhraeus,
The annual general meeting further resolved that board remuneration shall be paid with
The annual general meeting finally resolved in accordance with the proposal from the Nomination Committee to re-elect
Resolution on instruction for the Nomination Committee
The annual general meeting resolved in accordance with the proposal from the Nomination Committee that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall be comprised of three members, representing the three largest registered owners in terms of votes as of
Resolution on implementation of a long-term incentive program
The annual general meeting resolved in accordance with the proposal from the board of directors to implement a long-term incentive program for two senior executives and one key person in the company based on issue of warrants.
The incentive program shall comprise a maximum of 142,000 warrants. Each warrant entitles the right to subscribe for one new share in the company for a subscription price per share corresponding to 200 per cent of the volume weighted average price according to
In case all warrants issued in connection with the incentive program are exercised for subscription of new shares, a total of 142,000 new shares will be issued, which corresponds to a dilution of approximately 0.49 per cent of the company's share capital and votes after full dilution, calculated on the number of shares that will be added upon full utilization of all warrants issued under the incentive program.
For further information, please contact:
Christer Fåhraeus
CEO,
Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
https://news.cision.com/eql-pharma/r/bulletin-from-the-annual-general-meeting-in-eql-pharma-ab-on-17-august-2021,c3397407
https://mb.cision.com/Main/11664/3397407/1454844.pdf
(c) 2021 Cision. All rights reserved., source